Clinical Trial Update: Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Participants With Alzheimer's Disease (MK-4305-061) [Phase 3]

View source ↗

Summary

Phase 3 trial assessing safety and efficacy of suvorexant for insomnia in individuals with Alzheimer’s disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Sleep Initiation and Maintenance Disorders

Drugs mentioned

• Suvorexant (suvorexant)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Sleep Initiation and Maintenance Disorders, Alzheimer Disease | Phase 3 | Status: COMPLETED | Results posted: 2019-10-16